Literature DB >> 23042641

Protein phosphatase 2A Cα regulates osteoblast differentiation and the expressions of bone sialoprotein and osteocalcin via osterix transcription factor.

Hirohiko Okamura1, Kaya Yoshida, Di Yang, Tatsuji Haneji.   

Abstract

Serine/threonine protein phosphatase 2A (PP2A) participates in regulating many important physiological processes such as cell cycle, growth, apoptosis, and signal transduction. Osterix is a zinc-finger-containing transcription factor that is essential for osteoblast differentiation and regulation of many bone-related genes. We have recently reported that decrease in α-isoform of PP2A catalytic subunit (PP2A Cα) accelerates osteoblast differentiation through the expression of bone-related genes. In this study, we further examined the role of PP2A Cα in osteoblast differentiation by establishing the stable cell lines that overexpress PP2A Cα. Overexpression of PP2A Cα reduced alkaline phosphatase (ALP) activity. Osteoblast differentiation and mineralization were also decreased in PP2A Cα-overexpressing cells, with reduction of bone-related genes including osterix, bone sialoprotein (Bsp), and osteocalcin (OCN). Luciferase assay showed that the transcriptional activity of the Osterix promoter region was decreased in PP2A Cα-overexpressing cells. Introduction of ectopic Osterix rescued the expression of Bsp and OCN in PP2A Cα-overexpressing cells. These results indicate that PP2A Cα and its activity play a negative role in osteoblast differentiation and Osterix is a key factor responsible for regulating the expressions of Bsp and OCN during PP2A Cα-mediated osteoblast differentiation.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23042641     DOI: 10.1002/jcp.24250

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  9 in total

1.  The cytoskeleton meets the skeleton. Focus on "Deficiency of the intermediate filament synemin reduces bone mass in vivo".

Authors:  Omar Skalli
Journal:  Am J Physiol Cell Physiol       Date:  2016-10-26       Impact factor: 4.249

2.  Relationship between osteoporosis and benign paroxysmal positional vertigo based on evidence-based medicine and bioinformatics.

Authors:  Tuanmao Guo; Yanli Xing; Haiyun Zhu; Lan Yang; Yuan Xiao; Jiang Xu
Journal:  Arch Osteoporos       Date:  2021-11-15       Impact factor: 2.617

3.  Protein phosphatase 2A Cα regulates proliferation, migration, and metastasis of osteosarcoma cells.

Authors:  Di Yang; Hirohiko Okamura; Hiroyuki Morimoto; Jumpei Teramachi; Tatsuji Haneji
Journal:  Lab Invest       Date:  2016-09-12       Impact factor: 5.662

4.  Histone demethylase Jmjd3 regulates osteoblast differentiation via transcription factors Runx2 and osterix.

Authors:  Di Yang; Hirohiko Okamura; Yoshiki Nakashima; Tatsuji Haneji
Journal:  J Biol Chem       Date:  2013-10-08       Impact factor: 5.157

5.  Beneficial effects of sulfonamide‑based gallates on osteoblasts in vitro.

Authors:  Li Huang; Pan Jin; Xiao Lin; Cuiwu Lin; Li Zheng; Jinmin Zhao
Journal:  Mol Med Rep       Date:  2017-01-24       Impact factor: 2.952

Review 6.  Role of Protein Phosphatase 2A in Osteoblast Differentiation and Function.

Authors:  Hirohiko Okamura; Kaya Yoshida; Hiroyuki Morimoto; Jumpei Teramachi; Kazuhiko Ochiai; Tatsuji Haneji; Akihito Yamamoto
Journal:  J Clin Med       Date:  2017-02-23       Impact factor: 4.241

Review 7.  The Roles of Histone Demethylase Jmjd3 in Osteoblast Differentiation and Apoptosis.

Authors:  Di Yang; Bo Yu; Haiyan Sun; Lihong Qiu
Journal:  J Clin Med       Date:  2017-02-23       Impact factor: 4.241

Review 8.  Exosome mediated biological functions within skeletal microenvironment.

Authors:  Zhikun Wang; Zhonghan Zhao; Bo Gao; Lingli Zhang
Journal:  Front Bioeng Biotechnol       Date:  2022-07-22

9.  Stimulation of osteoclast formation by RANKL requires interferon regulatory factor-4 and is inhibited by simvastatin in a mouse model of bone loss.

Authors:  Yoshiki Nakashima; Tatsuji Haneji
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.